A V D'Amico

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 18:3240-6. 2000
  2. ncbi Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 18:1164-72. 2000
  3. ncbi Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer
    A D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Endourol 14:367-70. 2000
  4. ncbi Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
    A V D'Amico
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Department of Radiation Therapy, Harvard Medical School, 75 Francis St, L 2 Level, Boston, MA 02115, USA
    JAMA 284:1280-3. 2000
  5. ncbi Combined-modality staging for localized adenocarcinoma of the prostate
    A V D'Amico
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 15:1049-59; discussion 1060-2, 1064-5, 1069-70,1073-5. 2001
  6. ncbi Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
    A D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Urology 58:78-82. 2001
  7. ncbi Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score </= 7
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 89:1810-7. 2000
  8. ncbi Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Urol 4:171-5;discussion 177. 2000
  9. ncbi The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 49:679-84. 2001
  10. ncbi A practical method to achieve prostate gland immobilization and target verification for daily treatment
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 51:1431-6. 2001

Detail Information

Publications30

  1. ncbi Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 18:3240-6. 2000
    ..This study was performed to estimate 2-year PSA failure rates on the basis of readily available clinical and pathologic factors to identify patients for whom effective adjuvant systemic therapy is needed...
  2. ncbi Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 18:1164-72. 2000
    ..To determine the clinical utility of the percentage of positive prostate biopsies in predicting prostate-specific antigen (PSA) outcome after radical prostatectomy (RP) for men with PSA-detected or clinically palpable prostate cancer...
  3. ncbi Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer
    A D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Endourol 14:367-70. 2000
    ..A real-time three-dimensional magnetic resonance imaging (MRI)-guided implant technique has been designed and implemented. This report summarizes the dosimetry achieved and the acute morbidity in the first patients...
  4. ncbi Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
    A V D'Amico
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Department of Radiation Therapy, Harvard Medical School, 75 Francis St, L 2 Level, Boston, MA 02115, USA
    JAMA 284:1280-3. 2000
    ....
  5. ncbi Combined-modality staging for localized adenocarcinoma of the prostate
    A V D'Amico
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 15:1049-59; discussion 1060-2, 1064-5, 1069-70,1073-5. 2001
    ....
  6. ncbi Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
    A D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Urology 58:78-82. 2001
    ..Trials currently underway will examine the efficacy of ADT (4 to 6 months in duration) in patients with clinically localized prostate cancer with >/=1 high-risk features...
  7. ncbi Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score </= 7
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 89:1810-7. 2000
    ..Whether patients who are diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score </= 7 (micro PC) have potentially life-threatening disease if they are not treated is unknown...
  8. ncbi Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts 02215, USA
    Mol Urol 4:171-5;discussion 177. 2000
    ....
  9. ncbi The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 49:679-84. 2001
    ....
  10. ncbi A practical method to achieve prostate gland immobilization and target verification for daily treatment
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 51:1431-6. 2001
    ..A practical method to achieve prostate immobilization and daily target localization for external beam radiation treatment is described...
  11. ncbi Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215 USA
    Int J Radiat Oncol Biol Phys 45:1227-33. 1999
    ....
  12. ncbi The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy
    A V D'Amico
    Dana Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 45:847-51. 1999
    ..Specific attention is given to the patient subgroup with biopsy Gleason 3 + 4 vs. 4 + 3...
  13. ncbi Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 15:1465-9. 1997
    ....
  14. ncbi Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 16:3094-100. 1998
    ..This study was performed to validate or refute the prognostic value of the previously defined calculated prostate cancer volume (cV(Ca))...
  15. ncbi Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Mass 02215, USA
    JAMA 280:969-74. 1998
    ..Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known...
  16. ncbi Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?
    A V D'Amico
    Joint Center for Radiation Therapy, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 43:587-90. 1999
    ..The frequency of prostate cancer in this location as a function of the pre-treatment prostate specific antigen (PSA), biopsy Gleason score, and 1992 American Joint Commission on Cancer Staging (AJCC) was determined...
  17. ncbi Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, and Department of Pathology, Brigham and Women s Hospital, Boston, MA 02215, USA
    J Clin Oncol 17:168-72. 1999
    ....
  18. ncbi Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy
    A V D'Amico
    Dana Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 45:841-6. 1999
    ....
  19. ncbi Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer
    C J Beard
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 58:19-24. 2004
    ....
  20. ncbi Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 14:1770-7. 1996
    ....
  21. ncbi Optimizing patient selection for prostate monotherapy
    A K Lee
    Joint Center for Radiation Therapy, Harvard Medical School, 330 Brookline Avenue, 5th Floor, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 49:673-7. 2001
    ....
  22. ncbi Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02747, USA
    Int J Radiat Oncol Biol Phys 35:273-9. 1996
    ..A new clinical pretreatment quantity that closely approximates the true prostate cancer volume is defined...
  23. pmc High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?
    B A Mahal
    Harvard Medical School, Boston
    Ann Oncol 26:1390-5. 2015
    ..We evaluated whether prostate-specific antigen (PSA) anxiety or health literacy are associated with use of early salvage ADT among men with recurrent prostate cancer after radiotherapy...
  24. ncbi A clinical method for real-time dosimetric guidance of transperineal 125I prostate implants using interventional magnetic resonance imaging
    R A Cormack
    Joint Center for Radiation Therapy, Department of Radiation Oncology, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 46:207-14. 2000
    ..The clinical utility of an interventional magnetic resonance (IMR)-guided implant technique with real-time dosimetric feedback is presented...
  25. ncbi Optimizing target coverage by dosimetric feedback during prostate brachytherapy
    R A Cormack
    Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 48:1245-9. 2000
    ..The significance of needle misplacement and the clinical utility of dosimetric feedback were analyzed in the setting of interventional magnetic resonance (IMR) guided prostate brachytherapy...
  26. ncbi A software system for interventional magnetic resonance image-guided prostate brachytherapy
    H M Kooy
    Joint Center for Radiation Therapy, Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Comput Aided Surg 5:401-13. 2000
    ..The system permits the surgeon and patient to complete all phases of treatment in one setting...
  27. ncbi Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study
    R G Prosnitz
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 45:563-6. 1999
    ..Potential predictors of response to Flomax were evaluated...
  28. ncbi Towards enzyme activated antiprostatic agents
    G B Jones
    Department of Chemistry, Northeastern University, Boston, MA 02115, USA
    Bioorg Med Chem Lett 10:1987-9. 2000
    ..The prodrug system undergoes activation with PSA or alpha-chymotrypsin, and shows selective cytotoxicity in a PSA secreting cell line...
  29. pmc A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion
    C A Lago-Hernandez
    Harvard Medical School, Boston Department of Medical Oncology Genitourinary Division, Dana Farber Cancer Institute, Boston
    Ann Oncol 26:1396-401. 2015
    ....
  30. doi The association between race and treatment regret among men with recurrent prostate cancer
    B A Mahal
    Harvard Medical School, Boston, MA, USA
    Prostate Cancer Prostatic Dis 18:38-42. 2015
    ..To examine the impact of race on treatment regret among men with recurrent prostate cancer after surgery or radiation...